DGAP-News
Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015
DGAP-News: 4SC AG / Key word(s): Research Update
Press Release: 4SC presents new immunotherapeutic activity data of its
epigenetic cancer drug resminostat at the ECCO ITOC conference 2015
26.03.2015 / 07:30
---------------------------------------------------------------------
Press Release
4SC presents new immunotherapeutic activity data of its epigenetic cancer
drug resminostat at the ECCO ITOC conference 2015
Planegg-Martinsried, Germany, 26 March 2015 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for cancer and autoimmune diseases, today presents new data
on immunotherapeutic effects achieved with 4SC's epigenetic cancer drug
resminostat. The selected presentation will be held today, 26 March 2015,
11:00am CET at the ECCO ITOC conference 2015 in Munich, Germany.
The presentation will cover new preclinical data demonstrating
immunomodulating effects of the HDAC inhibitor resminostat, thus
potentially further contributing to its anti-tumoral activity, in
particular enhancing response rates. Resminostat has shown multiple
positive effects both by re-programming cancer cells and by enhancing the
immune system's defence mechanism against cancer cells.
The data indicate the ability of resminostat to help considerably improve
the effect of checkpoint inhibitors (PD1/PDL1) and other immunotherapeutic
approaches in oncology such as antibodies (e.g. rituximab) or
immunostimulating agents (e.g. TLR ligands), when applied in combination
therapy with these drugs in the clinic.
Dr Daniel Vitt, Chief Scientific Officer and Chief Development Officer of
4SC, said: "We are highly excited about the new data demonstrating multiple
immunotherapeutic effects of our lead oncology product resminostat. We
believe that this data potentially opens up new avenues for safe and
efficacious combination therapies with immune checkpoint inhibitors and
immunotherapeutic antibodies. We are currently further evaluating the data
in animal models and we are excited to be creating potential further
clinical options in the future."
The scientific findings in detail
Resminostat effects on mechanisms affecting anti-tumoral immune responses
were analysed in hepatocellular HepG2, Huh7, and SNU475 and adenocarcinomic
A549 cellular systems. It was shown that resminostat strongly reduced the
expression of immunosuppression mediating enzymes, IDO1 and ARG1 thus
Press Release
4SC presents new immunotherapeutic activity data of its epigenetic cancer
drug resminostat at the ECCO ITOC conference 2015
Planegg-Martinsried, Germany, 26 March 2015 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for cancer and autoimmune diseases, today presents new data
on immunotherapeutic effects achieved with 4SC's epigenetic cancer drug
resminostat. The selected presentation will be held today, 26 March 2015,
11:00am CET at the ECCO ITOC conference 2015 in Munich, Germany.
The presentation will cover new preclinical data demonstrating
immunomodulating effects of the HDAC inhibitor resminostat, thus
potentially further contributing to its anti-tumoral activity, in
particular enhancing response rates. Resminostat has shown multiple
positive effects both by re-programming cancer cells and by enhancing the
immune system's defence mechanism against cancer cells.
The data indicate the ability of resminostat to help considerably improve
the effect of checkpoint inhibitors (PD1/PDL1) and other immunotherapeutic
approaches in oncology such as antibodies (e.g. rituximab) or
immunostimulating agents (e.g. TLR ligands), when applied in combination
therapy with these drugs in the clinic.
Dr Daniel Vitt, Chief Scientific Officer and Chief Development Officer of
4SC, said: "We are highly excited about the new data demonstrating multiple
immunotherapeutic effects of our lead oncology product resminostat. We
believe that this data potentially opens up new avenues for safe and
efficacious combination therapies with immune checkpoint inhibitors and
immunotherapeutic antibodies. We are currently further evaluating the data
in animal models and we are excited to be creating potential further
clinical options in the future."
The scientific findings in detail
Resminostat effects on mechanisms affecting anti-tumoral immune responses
were analysed in hepatocellular HepG2, Huh7, and SNU475 and adenocarcinomic
A549 cellular systems. It was shown that resminostat strongly reduced the
expression of immunosuppression mediating enzymes, IDO1 and ARG1 thus
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte